Get Started
Gattaca Genomics offers state-of-the-art Preimplantation Genetic Testing to help you achieve your family planning goals. At Gattaca, innovation is at our core.
As a pioneer in genetic diagnostics and reproductive technologies, Gattaca Genomics is proud to announce Institutional Review Board (IRB) approval for its multi-center study, "Embryo Assessment Utilizing Time-lapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing." This groundbreaking study will examine the relationship between embryo development and aneuploidy, a condition where embryos have an abnormal number of chromosomes.
Maximize your chances of a successful pregnancy with Preimplantation Genetic Testing for Aneuploidy (PGT-A) testing. Our advanced genetic screening assesses embryos for chromosomal abnormalities. Reduce the risk of a miscarriage increasing the likelihood of a healthy birth. Embrace peace of mind as you embark on your journey to parenthood.
Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a laboratory technique used in the field of assisted reproductive technology (ART) to assess the chromosomal status of embryos before they are implanted. This testing aims to improve the chances of a successful pregnancy by screening embryos for the correct number of chromosomes (euploid embryos) and embryos with chromosomal abnormalities (aneuploid embryos).
• The amplified DNA from each embryo is analyzed to determine the number of chromosomes present in each cell. This analysis is done by next-generation sequencing (NGS).
• By examining the chromosomal content, PGT-A can identify embryos with the correct number of chromosomes (euploid) and those with abnormal numbers (aneuploid).
• Once the chromosomal analysis is complete, embryos with the correct number of chromosomes are identified as euploid embryos.
• These euploid embryos are more likely to result in a successful pregnancy when transferred.
• The results of PGT-A are communicated to the fertility specialist and the individuals or couples undergoing fertility treatment, allowing them to make informed decisions about which embryos to transfer.
Gattaca Genomics offers preimplantation genetic testing for families facing inherited genetic conditions for monogenic disorders (PGT-M). PGT-M helps identify embryos that are non-carriers for some known genetic mutations. Empower your family’s future with careful, well-informed family planning.
List of diseases that can be screened for using PGT-M:
PGT-SR, or Preimplantation Genetic Testing for Structural Rearrangements, is a specialized form of preimplantation genetic testing (PGT) used in assisted reproductive technology (ART) to help individuals or couples with known structural chromosomal rearrangements, such as translocations, inversions, or deletions, have healthy pregnancies.
• Structural Chromosomal Rearrangements: Some individuals carry chromosomal rearrangements where parts of their chromosomes are altered in their structure. This can include translocations (where segments of chromosomes are exchanged), inversions (where a segment is flipped), or deletions (where a portion of a chromosome is missing). These rearrangements can lead to fertility issues, recurrent miscarriages, or the birth of children with chromosomal disorders.
